Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythomatosus

Robak, Ewa; Wierzbowska, Agnieszka; Chmiela, Magdalena; Kulczycka, Liliana; Sysa-Jędrejowska, Anna; Robak, Tadeusz

doi:https://doi.org/10.1155/MI/2006/17898

Mediators of Inflammation

On this page

Abstract References Copyright Related Articles

Research Communication | Open Access

Volume 2006 | Article ID 017898 | https://doi.org/10.1155/MI/2006/17898

Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythomatosus

Ewa Robak,¹Agnieszka Wierzbowska,²Magdalena Chmiela,³Liliana Kulczycka,¹Anna Sysa-Jędrejowska,¹and Tadeusz Robak²

Received01 Sept 2005

Accepted20 Oct 2005

Published05 Feb 2006

Abstract

We investigated the serum concentration of total metalloproteinase-9 (tMPP-9), active MMP-9 (aMMP-9), and tissue inhibitor of metalloproteinase-1 (TIMP-1) in a group of 41 patients with SLE and 20 healthy controls. Serum levels of tMMP-9 and TIMP-1 were assessed by an enzyme-linked immunosorbent assay (ELISA) and aMMP-9 by fluorometric assay. The tMMP-9 level was lower in SLE patients (mean 262 ng/mL) than in healthy volunteers (mean 325 ng/mL) (P=.048). Similarly, aMMP-9 level was lower in SLE patients (mean 121 ng/mL) than in control group (mean 169 ng/mL) (P=.0355) and lower in active SLE (mean 54 ng/mL) than in inactive disease (mean 99 ng/mL) (P=.033). TIMP-1 level was also lower in SLE patients (mean 181 ng/mL) than in control group (mean 233 ng/mL) (P=.004). In SLE patients, a positive correlation was found between tMMP-9 and aMMP-9 (ρ=0.568; P=.001). We also found a positive correlation of tMMP-9 and TIMP-1 with VEGF concentrations (ρ=0.450, P=.005 and ρ=0.387; P=.018, resp). tMMP-9, aMMP-9, and TIMP-1 serum levels are lower in SLE patients than in healthy control group.

References

D S Pisetsky, G Gilkeson, and E W St Clair, “Systemic lupus erythematosus. Diagnosis and treatment,” Medical Clinics of North America, vol. 81, no. 1, pp. 113–128, 1997.
View at: Google Scholar
A J Swaak, J C Nossent, and R J Smeenk, “Systemic lupus erythematosus,” International Journal of Clinical & Laboratory Research, vol. 22, no. 4, pp. 190–195, 1992.
View at: Google Scholar
M Walchner, M Meurer, G Plewig, and G Messer, “Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus,” International Journal of Dermatology, vol. 39, no. 5, pp. 383–388, 2000.
View at: Google Scholar
E Robak, A Wozniacka, A Sysa-Jedrzejowska, H Stepien, and T Robak, “Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity,” European Cytokine Network, vol. 12, no. 3, pp. 445–452, 2001.
View at: Google Scholar
H M Belmont, S B Abramson, and J T Lie, “Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium,” Arthritis & Rheumatism, vol. 39, no. 1, pp. 9–22, 1996.
View at: Google Scholar
E Robak, A Sysa-Jedrzejowska, and T Robak, “Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus,” Mediators of Inflammation, vol. 12, no. 5, pp. 293–298, 2003.
View at: Google Scholar
K L Talks and A L Harris, “Current status of antiangiogenic factors,” British Journal of Haematology, vol. 109, no. 3, pp. 477–489, 2000.
View at: Google Scholar
L J McCawley and L M Matrisian, “Matrix metalloproteinases: they're not just for matrix anymore!,” Current Opinion in Cell Biology, vol. 13, no. 5, pp. 534–540, 2001.
View at: Google Scholar
C Matache, M Stefanescu, C Dragomir et al., “Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus,” Journal of Autoimmunity, vol. 20, no. 4, pp. 323–331, 2003.
View at: Google Scholar
A H Baker, D R Edwards, and G Murphy, “Metalloproteinase inhibitors: biological actions and therapeutic opportunities,” Journal of Cell Science, vol. 115, no. pt 19, pp. 3719–3727, 2002.
View at: Google Scholar
J F Jr Woessner, “Matrix metalloproteinases and their inhibitors in connective tissue remodeling,” The FASEB Journal, vol. 5, no. 8, pp. 2145–2154, 1991.
View at: Google Scholar
E Lambert, E Dasse, B Haye, and E Petitfrere, “TIMPs as multifacial proteins,” Critical Reviews in Oncology/Hematology, vol. 49, no. 3, pp. 187–198, 2004.
View at: Google Scholar
D E Gomez, D F Alonso, H Yoshiji, and U P Thorgeirsson, “Tissue inhibitors of metalloproteinases: structure, regulation and biological functions,” European Journal of Cell Biology, vol. 74, no. 2, pp. 111–122, 1997.
View at: Google Scholar
L Guedez, W G Stetler-Stevenson, L Wolff et al., “In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1,” The Journal of Clinical Investigation, vol. 102, no. 11, pp. 2002–2010, 1998.
View at: Google Scholar
G S Makowski and M L Ramsby, “Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus,” Molecular Pathology : MP, vol. 56, no. 4, pp. 244–247, 2003.
View at: Google Scholar
J F Muñoz-Valle, M Vázquez-Del Mercado, T García-Iglesias et al., “T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients,” Clinical and Experimental Immunology, vol. 131, no. 2, pp. 377–384, 2003.
View at: Google Scholar
C Mawrin, A Brunn, C Röcken, and J M Schröder, “Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases,” Acta Neuropathologica, vol. 105, no. 4, pp. 365–372, 2003.
View at: Google Scholar
S Zucker, N Mian, M Drews et al., “Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity,” The Journal of Rheumatology, vol. 26, no. 1, pp. 78–80, 1999.
View at: Google Scholar
A Faber-Elmann, Z Sthoeger, A Tcherniack, M Dayan, and E Mozes, “Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus,” Clinical and Experimental Immunology, vol. 127, no. 2, pp. 393–398, 2002.
View at: Google Scholar
E Toubi, A Kessel, G Grushko, E Sabo, M Rozenbaum, and I Rosner, “The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity,” Clinical and Experimental Rheumatology, vol. 20, no. 2, pp. 221–224, 2002.
View at: Google Scholar
E M Tan, A S Cohen, J F Fries et al., “The 1982 revised criteria for the classification of systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 25, no. 11, pp. 1271–1277, 1982.
View at: Google Scholar
M H Liang, S A Socher, M G Larson, and P H Schur, “Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 32, no. 9, pp. 1107–1118, 1989.
View at: Google Scholar
A Wierzbowska, H Urbańska-Ryś, and T Robak, “Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma,” British Journal of Haematology, vol. 105, no. 2, pp. 412–419, 1999.
View at: Google Scholar
E Robak, A Wozniacka, A Sysa-Jedrzejowska, H Stepien, and T Robak, “Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus,” Lupus, vol. 11, no. 6, pp. 348–355, 2002.
View at: Google Scholar
Y Liu, M Zheng, W H Yin, and B Zhang, “Relationship of serum levels of HGF and MMP-9 with disease activity of patients with systemic lupus erythematosus,” Zhejiang Da Xue Xue Bao Yi Xue Ban, vol. 33, no. 4, pp. 340–343, 348, 2004.
View at: Google Scholar
M H Tayebjee, K T Tan, R J MacFadyen, and G Y Lip, “Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity,” Journal of Internal Medicine, vol. 257, no. 1, pp. 110–116, 2005.
View at: Google Scholar
M H Tayebjee, G Y Lip, A D Blann, and R J MacFadyen, “Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2,” Thrombosis Research, vol. 115, no. 3, pp. 205–210, 2005.
View at: Google Scholar

Copyright

Copyright © 2006 Ewa Robak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

216

Downloads

691

Citations